Crystal structure of human JMJD2A in complex with compound 14a

2-(2H-1,2,3-triazol-4-yl)pyridine-4-carboxylic acid

Optimisation of a triazolopyridine based histone demethylase inhibitor yields a potent and selective KDM2A (FBXL11) inhibitor.

JMJC DOMAIN-CONTAINING HISTONE DEMETHYLATION PROTEIN 3A, JUMONJI DOMAIN-CONTAINING PROTEIN 2A, JMJD2A

0.1M BIS-TRIS PH 5.9, 0.15M AMMONIUM SULFATE, 11% PEG3350

LYSINE-SPECIFIC DEMETHYLASE 4A (E.C.1.14.11.-)

OXIDOREDUCTASE, JUMONJIC, HISTONE DEMETHYLASE